PURPOSE: AlphaCor (Argus Biomedical Pty. Ltd., Perth, Australia) is an artificial, soft, one-piece keratoprosthesis (KPro) indicated for severe corneal conditions not treatable by a donor graft. To evaluate the efficacy and visual restoring of six patients with complete corneal opacification and deep neovascularizations treated with AlphaCor. METHODS: A retrospective review of six patients with a history of corneal opacification treated with keratoprosthesis surgery. AlphaCor synthetic cornea was implanted into the corneal stroma. During the follow-up time, slit-lamp and ultrasound examinations, best corrected visual acuity (BCVA), and intraocular pressure measurements were performed. RESULTS: Six eyes with corneal scarring and vascularizations in three to four quadrants of six patients to years of age underwent a keratoprosthesis procedure. The follow-up time was 13-36 months; mean 23 months. The operation procedure was not limited by severe complications. The preoperative BCVA was hand movement to light perception. The postoperative BCVA ranged between 20/200 and 80/100. Intraocular pressure was controlled in all cases. Three patients developed a melting of the anterior corneal lamella. The keratoprosthesis had to be explanted (15-34 months after implantation) and was replaced by a donor cornea. CONCLUSIONS: Further evaluation is needed to evaluate the role of AlphaCor as a keratoprosthesis.
PURPOSE:AlphaCor (Argus Biomedical Pty. Ltd., Perth, Australia) is an artificial, soft, one-piece keratoprosthesis (KPro) indicated for severe corneal conditions not treatable by a donor graft. To evaluate the efficacy and visual restoring of six patients with complete corneal opacification and deep neovascularizations treated with AlphaCor. METHODS: A retrospective review of six patients with a history of corneal opacification treated with keratoprosthesis surgery. AlphaCor synthetic cornea was implanted into the corneal stroma. During the follow-up time, slit-lamp and ultrasound examinations, best corrected visual acuity (BCVA), and intraocular pressure measurements were performed. RESULTS: Six eyes with corneal scarring and vascularizations in three to four quadrants of six patients to years of age underwent a keratoprosthesis procedure. The follow-up time was 13-36 months; mean 23 months. The operation procedure was not limited by severe complications. The preoperative BCVA was hand movement to light perception. The postoperative BCVA ranged between 20/200 and 80/100. Intraocular pressure was controlled in all cases. Three patients developed a melting of the anterior corneal lamella. The keratoprosthesis had to be explanted (15-34 months after implantation) and was replaced by a donor cornea. CONCLUSIONS: Further evaluation is needed to evaluate the role of AlphaCor as a keratoprosthesis.
Authors: C Hicks; G Crawford; T Chirila; S Wiffen; S Vijayasekaran; X Lou; J Fitton; M Maley; A Clayton; P Dalton; S Platten; B Ziegelaar; Y Hong; A Russo; I Constable Journal: Prog Retin Eye Res Date: 2000-03 Impact factor: 21.198
Authors: Celia R Hicks; Geoffrey J Crawford; Donald T Tan; Grant R Snibson; Gerard L Sutton; Tjahjono D Gondhowiardjo; Dennis S C Lam; Nicholas Downie Journal: Cornea Date: 2002-10 Impact factor: 2.651
Authors: Luo Luo Zheng; Vijay Vanchinathan; Roopa Dalal; Jaan Noolandi; Dale J Waters; Laura Hartmann; Jennifer R Cochran; Curtis W Frank; Charles Q Yu; Christopher N Ta Journal: J Biomed Mater Res A Date: 2015-03-27 Impact factor: 4.396
Authors: Haleh Bakhshandeh; Masoud Soleimani; Saied Shah Hosseini; Hassan Hashemi; Iman Shabani; Abbas Shafiee; Amir Houshang Behesht Nejad; Mohammad Erfan; Rassoul Dinarvand; Fatemeh Atyabi Journal: Int J Nanomedicine Date: 2011-07-14
Authors: Michel Haagdorens; Sara Ilse Van Acker; Veerle Van Gerwen; Sorcha Ní Dhubhghaill; Carina Koppen; Marie-José Tassignon; Nadia Zakaria Journal: Stem Cells Int Date: 2015-12-14 Impact factor: 5.443